Gainers

• Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release, Q2 earnings came out today.
• GRI Bio (NASDAQ:GRI) stock moved upwards by 32.1% to $2.25. The company's market cap stands at $3.0 million.
• Alamar Biosciences (NASDAQ:ALMR) stock increased by 30.81% to $36.62. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q2 earnings report came out yesterday.
• Mereo BioPharma Group (NASDAQ:MREO) shares increased by 29.4% to $0.35. The company's market cap stands at $43.4 million. The company's, Q2 earnings came out today.
• Jasper Therapeutics (NASDAQ:JSPR) stock rose 21.29% to $0.97. The market value of their outstanding shares is at $26.5 million.
• Aurora Cannabis (NASDAQ:ACB) shares increased by 20.58% to $3.48. The company's market cap stands at $179.0 million. The company's, Q1 earnings came out 4 days ago.

Losers

• PDS Biotechnology (NASDAQ:PDSB) shares fell 63.4% to $0.27 during Tuesday's regular session. The company's market cap stands at $40.8 million.
• Curis (NASDAQ:CRIS) shares fell 34.43% to $2.4. The market value of their outstanding shares is at $7.1 million.
• Pyxis Oncology (NASDAQ:PYXS) shares declined by 30.55% to $2.66. The company's market cap stands at $242.6 million.
• Xtant Medical Holdings (AMEX:XTNT) stock fell 26.01% to $0.33. The market value of their outstanding shares is at $62.5 million. The company's, Q2 earnings came out today.
• Silexion Therapeutics (NASDAQ:SLXN) stock declined by 24.67% to $1.13. The company's market cap stands at $1.5 million.
• AIxCrypto Hldgs (NASDAQ:AIXC) stock fell 18.87% to $0.64. The company's market cap stands at $15.9 million. The company's, Q3 earnings came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.